Comprehensive Gene Panel:
Covers 62 genes associated with 19 hereditary cancer types.
Hereditary Cancer Screening Assay
Genetic Testing for Hereditary Cancer Risk
Hereditary Cancer Screening Assay
The assay can assess the hereditary cancer risk of subjects and detect the whole exome region of genes related to cancer risk. Combined with the Geneplus Baseline Database, it can realize the one-time assessment of the genetic risk of 18 types of tumors in women and 17 types in men.
Full-Spectrum Variant Profiling
Delivers comprehensive variant detection for hereditary cancer risk assessment.
Intuitive Result Output
Generates user-friendly reports for health management and targeted prevention.
Indications and Clinical Utility
Eligible
Population
Individuals with Family History
Family members of cancer patients (high-risk population)
Cancer Patients
Patients with strong hereditary links, including: Breast/ovarian cancer, colorectal cancer, or multiple primary cancers
Test
Result
Negative
Positive
Clinical
Utility
Health Management
Non-carriers can alleviate psychological stress from a "family cancer history". No pathogenic mutations detected; hereditary cancer risk is lower than the general population.
Precision Prevention
Targeted prevention and early detection/intervention for carriers. Carriers can develop prevention and intervention plans based on their specific hereditary cancer risks.
Precision Treatment
Reference for patient treatment guidance. Pathogenic mutation carriers may be sensitive to certain drugs (e.g., PARP inhibitors, platinum-based agents).
Multiple Primary Cancer Risk Assessment
Reference for multiple primary cancer risk assessment. Breast cancer patients with BRCA mutations have a 2-7x higher cumulative risk of contralateral breast cancer compared to non-carriers.